Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma

被引：0
|
作者：
Lee, Jae Woo
Son, Jun Hyuk
Lee, Ban Seok
Lee, Sang Hyub
Jang, Dong Kee
Chung, Kwang Hyun
Ryu, Ji Kon
Kim, Yong-Tae
机构：
[1] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Internal Med, Seoul 151, South Korea
[2] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Liver Res Inst, Seoul 151, South Korea
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-8-51
引用
收藏
页码：121 / 121
页数：1
相关论文
共 50 条
  • [21] Gemcitabine-based Adjuvant Chemotherapy for Patients with Advanced Gallbladder Cancer
    Nakamura, Masafumi
    Nakashima, Hiroshi
    Abe, Toshiya
    Ensako, Takaaki
    Yoshida, Koji
    Hino, Keisuke
    ANTICANCER RESEARCH, 2014, 34 (06) : 3125 - 3129
  • [22] CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
    H S Wasan
    G M Springett
    C Chodkiewicz
    R Wong
    J Maurel
    C Barone
    B Rosbrook
    A D Ricart
    S Kim
    J-P Spano
    British Journal of Cancer, 2009, 101 : 1162 - 1167
  • [23] Pretreatment level of CA 19-9 is a prognostic factor in advanced pancreatic cancer treated with chemotherapy
    Gansl, R. C.
    Reis, P. T.
    Tabacof, J.
    Simon, S. D.
    Machado, M. C.
    Borghesi, G.
    Saad, E. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Postresection CA 19-9 Value as a Prognostic Factor Response
    Seo, Yuji
    Kinsella, Timothy J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (01): : 107 - 107
  • [25] Postresection CA 19-9 Value as a Prognostic Factor Response
    Seo, Yuji
    Kinsella, Timothy J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (03): : 320 - 320
  • [26] CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer
    Nakai, Yousuke
    Kawabe, Takao
    Isayama, Hiroyuki
    Sasaki, Takashi
    Yagioka, Hiroshi
    Yashima, Yoko
    Kogure, Hirofumi
    Arizumi, Toshihiko
    Togawa, Osamu
    Ito, Yukiko
    Matsubara, Saburo
    Hirano, Kenji
    Sasahira, Naoki
    Tsujino, Takeshi
    Tada, Minoru
    Omata, Masao
    ONCOLOGY, 2008, 75 (1-2) : 120 - 126
  • [27] Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
    Stemmler, J
    Stieber, P
    Szymala, AM
    Schalhorn, A
    Schermuly, MM
    Wilkowski, R
    Helmberger, T
    Lamerz, R
    Stoffregen, C
    Niebler, K
    Garbrecht, M
    Heinemann, V
    ONKOLOGIE, 2003, 26 (05): : 462 - 467
  • [28] Prognostic Value of Carbohydrate Antigen 19-9 and the Surgical Margin in Extrahepatic Cholangiocarcinoma
    Yamamoto, Ryusei
    Sugiura, Teiichi
    Ashida, Ryo
    Ohgi, Katsuhisa
    Yamada, Mihoko
    Otsuka, Shimpei
    Uesaka, Katsuhiko
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2022, 6 (02): : 307 - 315
  • [29] Prognostic Value of Preoperative CEA and CA 19-9 Levels in Patients with Colorectal Cancer
    Basbug, Murat
    Arikanoglu, Zulfu
    Bulbuller, Nurullah
    Cetinkaya, Ziya
    Aygen, Erhan
    Akbulut, Sami
    Satici, Omer
    HEPATO-GASTROENTEROLOGY, 2011, 58 (106) : 400 - 405
  • [30] CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy.
    Patel, B
    Heilburn, L
    Khanna, A
    Venkatramanamoorthy, R
    Shields, A
    Philip, P
    Zalupski, M
    El-Rayes, B
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 355S - 355S
12345